Ticker: VERU

Veru Inc. (NASDAQ: VERU) Quick read: management has executed strategic asset sales (FC2) and extinguished a residual royalty liability, which produced one‑time cash and non‑operating gains. At the same time the company remains a pre‑revenue biopharma with ongoing R&D (enobosarm, sabizabulin), lar...

Veru Inc. (NASDAQ: VERU) is navigating significant challenges and a pivotal transition following the sale of its FC2 business and the ongoing development of its drug candidates. This quarterly report presents a mix of positive and negative aspects reflected in the latest income statement. Income ...

Company Overview: Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company focusing on developing novel medicines for cardiometabolic and inflammatory diseases. Their drug development includes enobosarm for fat loss in elderly patients and sabizabulin for treating atherosclerot...